Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Uncovering the differences in tumor suppressor function between SMARCA2 and SMARCA4 in rhabdoid tumors

FY 2022-23

Summary
Cancer remains one the leading causes of death in Canada, with about 2 out of 5 Canadians being diagnosed with cancer within their lifetime, and 1 in 4 Canadians dying of cancer. This disease is caused by dysregulated cell proliferation, which can lead to serious pathological consequences for the cancer patients. Many different genes, even within the same cancer subtype can be responsible for cancer. Because most cancers have different genetic background, it is difficult to find therapies that would be able to treat all cancer patients. There are some cancers however, like Atypical Teratoid Rhabdoid Tumours (ATRT), which are rhabdoid tumours which have been shown to have quiescent genomes. ATRT is also a rare highly aggressive pediatric cancer which affects young children and infants (ages 1 to 5) that arises in the brain. ATRT is genetically characterized by inactivating mutations in subunits of SWI/SNF chromatin remodelling complex, SMARCB1 (98% of cases) and SMARCA4 (2%), along with silencing of SMARCA2. Both SMARCA2 and SMARCA4 are mutually exclusive ATPase subunits of the SWI/SNF complex, whose subunits are mutated in >20% of cancers. ATRT has poor prognosis, most patients do not survive. A study has previously shown that restoration of SMARCA2 expression in SMARCA2-deficient rhabdoid tumours leads to growth inhibition, despite most of them being SMARCA4 proficient. Both SMARCA4 and SMARCA2 were previously thought to have similar tumor suppressor functions, however this suggests that SMARCA2 would play a unique tumour suppressor function, different from SMARCA4’s. This unique function of SMARCA2 might indicate a tumour suppressor pathway in which it plays a crucial role in rhabdoid tumours, which could be used to provide new treatment options for ATRT patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486110
Name
Sansal Racim
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Uncovering the differences in tumor suppressor function between SMARCA2 and SMARCA4 in rhabdoid tumors
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atrt; Cancer; Sccoht; Smarca2; Smarca4; Swi/Snf Complex
Abstract
Cancer remains one the leading causes of death in Canada, with about 2 out of 5 Canadians being diagnosed with cancer within their lifetime, and 1 in 4 Canadians dying of cancer. This disease is caused by dysregulated cell proliferation, which can lead to serious pathological consequences for the cancer patients. Many different genes, even within the same cancer subtype can be responsible for cancer. Because most cancers have different genetic background, it is difficult to find therapies that would be able to treat all cancer patients. There are some cancers however, like Atypical Teratoid Rhabdoid Tumours (ATRT), which are rhabdoid tumours which have been shown to have quiescent genomes. ATRT is also a rare highly aggressive pediatric cancer which affects young children and infants (ages 1 to 5) that arises in the brain. ATRT is genetically characterized by inactivating mutations in subunits of SWI/SNF chromatin remodelling complex, SMARCB1 (98% of cases) and SMARCA4 (2%), along with silencing of SMARCA2. Both SMARCA2 and SMARCA4 are mutually exclusive ATPase subunits of the SWI/SNF complex, whose subunits are mutated in >20% of cancers. ATRT has poor prognosis, most patients do not survive. A study has previously shown that restoration of SMARCA2 expression in SMARCA2-deficient rhabdoid tumours leads to growth inhibition, despite most of them being SMARCA4 proficient. Both SMARCA4 and SMARCA2 were previously thought to have similar tumor suppressor functions, however this suggests that SMARCA2 would play a unique tumour suppressor function, different from SMARCA4’s. This unique function of SMARCA2 might indicate a tumour suppressor pathway in which it plays a crucial role in rhabdoid tumours, which could be used to provide new treatment options for ATRT patients.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sansal, Racim
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~